This brand name is authorized in Italy, New Zealand, Poland
The drug ASAMAX contains one active pharmaceutical ingredient (API):
|
1
Mesalazine
UNII 4Q81I59GXC - MESALAMINE
|
|
Mesalazine is an aminosalicylate. The mechanism of action of mesalazine is not fully understood, but appears to have a topical anti-inflammatory effect on the colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase and lipoxygenase pathways, is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalazine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin production in the colon. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| A07EC02 | Mesalazine | A Alimentary tract and metabolism → A07 Antidiarrheals, intestinal antiinflammatory/antiinfective agents → A07E Intestinal antiinflammatory agents → A07EC Aminosalicylic acid and similar agents |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: IT | Agenzia del Farmaco | Identifier(s): 034298024, 034298051 |
| Country: NZ | Medicines and Medical Devices Safety Authority | Identifier(s): 12211, 12213 |
| Country: PL | Rejestru Produktów Leczniczych | Identifier(s): 100127789, 100127795, 100127803, 100127810 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
